Topics:
Breast Cancer • Medical Oncology
Do you have a preference for a CDK4/6 inhibitor for first line metastatic HR positive breast cancer in combination with faslodex?
Answer from: Medical Oncologist at Community Practice
I do not have a preference for a CDK 4/6 inhibitor when given with fulvestran for metastatic ER+/Her-2 - breast cancer. Both palbociclib and abemaciclib are approved in combination with fulvestrant. There are differences in terms of dosing, schedule, and side effects. But, these features don't sugge...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
There is actually some mature data now on overall survival. The MONARCH 2 clinical trial evaluated the combination of fulvestrant and abemaciclib showing a prolonged median overall survival in both premenopausal and postmenopausal women. The MONALEESA-7 trial has shown an overall survival, but this ...
Answer from: Medical Oncologist at Academic Institution
At ESMO 2019, MONALEESA-3 results were presented; ribociclib added to fulvestrant in first- and second-line setting in post menopausal women showed improvement in OS, and OS reached statistical significance when both subgroups were combined. So, all three agents improve OS when combined with fulvest...